Paul Taylor

Bial has stopped development in a subpopulation of Parkinson's disease patients after its phase 2b trial missed its primary and key secondary efficacy endpoints.

Whatever the motive, past time to move him up. By Paul Taylor |

The changes support accuracy across diverse patient populations, skin tones and clinical care settings.

Sometimes, the best moves are the ones you don't make. During this past offseason, we covered the speculation surrounding the Mariners potentially trading for Ketel Marte.

The defender was considering a career in construction before a week-long trial that changed the course of his life

Sanofi has stopped a phase 3 autoimmune clinical trial early after an interim analysis found the therapy was “unlikely to provide sufficient

It sure feels like only the M's can stop the M's. By Paul Taylor |

The company plans to eliminate 119 positions by mid-December as part of a phased transfer of some production from the manufacturing site.

Just don't get too excited about this one. By Paul Taylor | When it comes to first-rounders who the Mariners traded for, J.P.

There was a surprise on Forest's retained list - the left back who has not played a competitive first-team game since arriving in 2022